The world journal of men's health · 2026
Efficacy of Elaeagnus multiflora and Cynanchum wilfordii Complex Extract on Male Lower Urinary Tract Symptoms: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Hwa Jong, Kim Tae Hyung, Kim Soomin, Cho Hyuk Jin, Ha U-Syn, Kim Sae Woong, Jo Ha-Neul, Kim Jaeyong, Shin Dongho, Bae Woong Jin
Аннотация
PURPOSE: Lower urinary tract symptoms (LUTS) in men substantially impair quality of life and are commonly treated with alpha-blockers or 5-alpha reductase inhibitors, which may cause adverse effects. Elaeagnus multiflora and Cynanchum wilfordii, traditional herbal remedies, have shown potential benefits in testosterone regulation and benign prostatic hyperplasia (BPH); however, clinical evidence supporting their efficacy in LUTS remains limited. This study evaluated the efficacy and safety of the E. multiflora and C. wilfordii complex (NET1701) in men with LUTS.
MATERIALS AND METHODS: In this randomized, double-blind, placebo-controlled trial, 100 men aged 40-80 years with moderate LUTS (International Prostate Symptom Score [IPSS] 8-19) were randomized to receive NET1701 (325 mg/d) or placebo for 12 weeks. The primary outcome was the change in total IPSS from baseline to 12 weeks. Secondary outcomes included IPSS subscores, maximum urinary flow rate (Qmax), post-void residual volume (PVR), serum testosterone levels, and safety.
RESULTS: At 12 weeks, the NET1701 group showed a significantly greater reduction in total IPSS compared with placebo (-5.67±3.86 vs. -1.00±4.30; p<0.0001). Significant improvements were observed in several IPSS subscores, including incomplete emptying, frequency, intermittency, and weak stream (p<0.05). Although Qmax and PVR did not differ significantly between groups, urinary symptom-related quality-of-life scores improved significantly in the NET1701 group (p<0.0001). NET1701 was well tolerated, with no severe adverse events reported.
CONCLUSIONS: The E. multiflora and C. wilfordii complex (NET1701) significantly improved LUTS severity and quality of life without notable adverse effects. These findings suggest that NET1701 may represent a promising phytotherapeutic option for the management of male LUTS. Further long-term studies are needed to confirm its sustained efficacy and safety.
MATERIALS AND METHODS: In this randomized, double-blind, placebo-controlled trial, 100 men aged 40-80 years with moderate LUTS (International Prostate Symptom Score [IPSS] 8-19) were randomized to receive NET1701 (325 mg/d) or placebo for 12 weeks. The primary outcome was the change in total IPSS from baseline to 12 weeks. Secondary outcomes included IPSS subscores, maximum urinary flow rate (Qmax), post-void residual volume (PVR), serum testosterone levels, and safety.
RESULTS: At 12 weeks, the NET1701 group showed a significantly greater reduction in total IPSS compared with placebo (-5.67±3.86 vs. -1.00±4.30; p<0.0001). Significant improvements were observed in several IPSS subscores, including incomplete emptying, frequency, intermittency, and weak stream (p<0.05). Although Qmax and PVR did not differ significantly between groups, urinary symptom-related quality-of-life scores improved significantly in the NET1701 group (p<0.0001). NET1701 was well tolerated, with no severe adverse events reported.
CONCLUSIONS: The E. multiflora and C. wilfordii complex (NET1701) significantly improved LUTS severity and quality of life without notable adverse effects. These findings suggest that NET1701 may represent a promising phytotherapeutic option for the management of male LUTS. Further long-term studies are needed to confirm its sustained efficacy and safety.